Company Description
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States.
The company’s product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial.
It has license agreement with Meiji Seika Pharma Co., Ltd. to develop, manufacture, and commercialize tebipenem pivoxil and tebipenem HBr; and Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries.
Spero Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2013 |
| IPO Date | Nov 2, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 25 |
| CEO | Esther Rajavelu |
Contact Details
Address: 675 Massachusetts Avenue, 14th Floor Cambridge, Massachusetts 02139 United States | |
| Phone | 857 242 1600 |
| Website | sperotherapeutics.com |
Stock Details
| Ticker Symbol | SPRO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001701108 |
| CUSIP Number | 84833T103 |
| ISIN Number | US84833T1034 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Esther P. Rajavelu | Chief Executive Officer, President, Chief Financial Officer, Chief Business Officer, Treasurer and Director |
| Timothy Keutzer | Chief Operating Officer |
| John Raymond | Senior Vice President of Finance and Business Operations |
| Sheila Finan | Senior Vice President and Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 25, 2026 | 8-K | Current Report |
| Jun 23, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jun 22, 2026 | 8-K | Current Report |
| May 13, 2026 | 10-Q | Quarterly Report |
| May 13, 2026 | 8-K | Current Report |
| Apr 27, 2026 | ARS | Filing |
| Apr 27, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 27, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 13, 2026 | PRE 14A | Other preliminary proxy statements |
| Mar 26, 2026 | 8-K | Current Report |